Evidence map›Paper›PMID 26568258›Full record

ArticleNanoscale2015

Development and characterization of antibody reagents for detecting nanoparticles.

Supriya Ravichandran, Mark A Sullivan, Linda M Callahan, Karen L Bentley, Lisa A DeLouise

Abstract read
In one paragraph

Article in Nanoscale, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Supriya RavichandranDepartment of Biomedical Engineering, University of Rochester, Rochester, New York 14642, USA. Lisa_DeLouise@urmc.rochester.edu.
Mark A Sullivan
Linda M Callahan
Karen L Bentley
Lisa A DeLouise

Funding

Reagents to Enhance Detection of Raw and Biologically Transformed NanomaterialsR21OH009970 · OH · UNIVERSITY OF ROCHESTER · PI DELOUISE, LISA A · 2011 to 2012
$403k
NIOSH CDC HHS 1R21OH009970NIOSH CDC HHS R21 OH009970
6 · The paper itself

Abstract

The increasing use of nanoparticles (NPs) in technological applications and in commercial products has escalated environmental health and safety concerns. The detection of NPs in the environment and in biological systems is challenged by limitations associated with commonly used analytical techniques. In this paper we report on the development and characterization of NP binding antibodies, termed NProbes. Phage display methodology was used to discover antibodies that bind NPs dispersed in solution. We present a proof-of-concept for the generation of NProbes and their use for detecting quantum dots and titanium dioxide NPs in vitro and in an ex vivo human skin model. Continued development and refinement of NProbes to detect NPs that vary in composition, shape, size, and surface coating will comprise a powerful tool kit that can be used to advance nanotechnology research particularly in the nanotoxicology and nanotherapeutics fields.

Indexed as

AlbuminsHumansImmunohistochemistryIndicators and ReagentsMicroscopy, Electron, TransmissionNanomedicineNanoparticlesPeptide LibraryQuantum DotsSingle-Chain AntibodiesSkinTitaniumAlbuminsIndicators and ReagentsPeptide LibrarySingle-Chain AntibodiesTitaniumtitanium dioxide

Identifiers

PMID26568258
PMCPMC4685707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.